The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...

The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

Serabelisib (KP-001) was filed with Japan's regulatory authority in May as a therapy for the treatment of vascular ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

Life sciences equipment and consumable manufacturer Repligen has reached a deal to buy cell therapy specialist BioLife ...